Extended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndrome

Clinical and Experimental Rheumatology

Volumn 30, Issue SUPPL. 70, 2012, Pages

  Herrmann, Kristine ^a   Gross, Wolfgang L ^a   Moosig, Frank ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Churg Strauss syndrome; IL 5; Mepoplizumab

Indexed keywords

EOSINOPHIL CATIONIC PROTEIN; GLUCOCORTICOID; MEPOLIZUMAB; METHOTREXATE;

ARTICLE; BIRMINGHAM VASCULITIS ACTIVITY SCORE; CHURG STRAUSS SYNDROME; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE ACTIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELAPSE; REMISSION; SCORING SYSTEM; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; CHURG-STRAUSS SYNDROME; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; EOSINOPHIL CATIONIC PROTEIN; FOLLOW-UP STUDIES; GERMANY; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; METHOTREXATE; RECURRENCE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84863763157     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. MOOSIG F, GROSS WL, HERRMANN K, BREMER JP, HELLMICH B: Targeting interleukin- 5 in refractory and relapsing Churg-Strauss syndrome. Ann Int Med 2011; 155: 341-3.
2. KIM S, MARIGOWDA G, OREN E, ISRAEL E, WECHSLER ME: Mepolizumab as a steroidsparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 2010; 125: 1336-43.
3. ROTHENBERG ME, KLION AD, ROUFOSSE FE et al.: Treatment of patients with the hypereosinophilic syndrome with mepolizumab. NEngl J Med 2008; 358:1215-28.
4. HATTORI N, ICHIMURA M, NAGAMATSU M et al.: Clinicopathological features of Churg- Strauss syndrome-associated neuropathy. Brain 1999; 122: 427-39.
5. BYSTROM J, AMIN K, BISHOP-BAILEY D: Analysing the eosinophil cationic protein - a clue to the function of the eosinophil granulocyte. Respir Res 2011; 12: 10.
6. SCHMITT WH, CSERNOK E, KOBAYASHI S, KLINKENBORG A, REINHOLD-KELLER E, GROSS WL: Churg-Strauss syndrome: serum markers of lymphocyte activation and endothelial damage. Arthritis Rheum 1998; 41: 445-52.
7. GUILPAIN P, AUCLAIR JF, TAMBY MC et al.: Serum eosinophil cationic protein. A marker of disease activity in Churg-Strauss syndrome. Ann NY Acad Sci 2007; 1107: 392-9.
8. LUQMANI RA, BACON PA, MOOTS RJ et al.: Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994; 87: 671-81.
9. HELLMICH B, FLOSSMANN O, GROSS WL et al.: EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007; 66: 605-17.
10. REINHOLD-KELLER E, DE GROOT K: Use of methotrexate in ANCA-associated vasculitides. Clin Exp Rheumatol 2010; 28: S178-82.
11. MUKHTYAR C, GUILLEVIN L, CID MC et al.: EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68: 310-7.
12. ARNING L, HOLLE JU, HARPER L et al.: Are there Specific Genetic Risk Factors For The Different Forms Of Anca-Associated Vasculitis? Ann Rheum Dis 2011; 70: 707-8.